Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

Last week, Fresenius Kabi announced the launch of STIMUFEND (pegfilgrastim-fpgk), a biosimilar to Amgen’s NEULASTA, in the United States. As we previously reported, STIMUFEND was Fresenius Kabi ...

In recent years, Cinfa Biotech used its resources to advance B12019, a biosimilar copy of Amgen’s chemotherapy-induced neutropenia drug Neulasta, through clinical trials. B12019 and Neulasta are ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta biosimilar to Accord BioPharma. About 50 employees who are associated with ...

Pegfilgrastim biosimilars, including Neulasta, are instrumental in preventing chemotherapy-induced neutropenia by stimulating white blood cell production and reducing infection risks. The Neulasta ...

The Niopeg is comparable to the reference biologic drug Neulasta. Nora Pharma ... receiving myelosuppressive anti-neoplastic drugs. The biosimilar Niopeg will be available in Canada in a prefilled ...